Q1 2022 Earnings Forecast for PepGen Inc. Issued By SVB Leerink (NASDAQ:PEPG)

PepGen Inc. (NASDAQ:PEPGGet Rating) – Stock analysts at SVB Leerink issued their Q1 2022 earnings per share estimates for shares of PepGen in a research report issued on Tuesday, May 31st. SVB Leerink analyst J. Schwartz forecasts that the company will earn ($0.89) per share for the quarter. SVB Leerink currently has a “Outperform” rating and a $40.00 target price on the stock. SVB Leerink also issued estimates for PepGen’s Q2 2022 earnings at ($0.66) EPS, Q3 2022 earnings at ($0.81) EPS, Q4 2022 earnings at ($1.01) EPS, FY2022 earnings at ($3.34) EPS, Q1 2023 earnings at ($0.53) EPS, Q2 2023 earnings at ($0.55) EPS, Q3 2023 earnings at ($0.58) EPS, Q4 2023 earnings at ($0.60) EPS, FY2023 earnings at ($2.26) EPS, FY2024 earnings at ($2.53) EPS, FY2025 earnings at ($2.46) EPS and FY2026 earnings at ($2.93) EPS.

Other equities analysts have also recently issued research reports about the stock. Bank of America assumed coverage on shares of PepGen in a research report on Tuesday. They set a “buy” rating and a $16.00 price target on the stock. Wedbush initiated coverage on shares of PepGen in a research note on Tuesday. They set an “outperform” rating and a $17.00 price objective on the stock. Finally, Stifel Nicolaus initiated coverage on shares of PepGen in a research note on Tuesday. They set a “buy” rating and a $24.00 price objective on the stock.

PepGen stock opened at $10.92 on Thursday. PepGen has a 1-year low of $7.82 and a 1-year high of $16.99.

PepGen Company Profile (Get Rating)

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen Inc is based in BOSTON.

See Also

Earnings History and Estimates for PepGen (NASDAQ:PEPG)

Want More Great Investing Ideas?

Receive News & Ratings for PepGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PepGen and related companies with MarketBeat.com's FREE daily email newsletter.